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Financial dGraft-versus-Host Disease Prophylaxis with Tacrolimus
and Mycophenolate Mofetil in HLA-Matched
Nonmyeloablative Transplant Recipients Is Associated
with Very Low Incidence of GVHD
and Nonrelapse Mortality
Waleed Sabry,1 Richard Le Blanc,2 Annie-Claude Labbe,3 Guy Sauvageau,1
Stephen Couban,4 Thomas Kiss,1 Lambert Busque,1 Sandra Cohen,1 Silvy Lachance,1
Denis-Claude Roy,1 Jean Roy1Incidenceof grade II-IVacute graft-versus-host disease (aGVHD) in nonmyeloablative (NMA) transplant recipients
remains high. To date, the ideal prophylaxis regimen, whichminimizes aGVHD and chronic GVHD (cGVHD), but
does not abrogate graft-versus-tumor (GVT) response, has not been described. Because tacrolimus is more po-
tent than cyclosporine (CSA), and because mycophenolate mofetil (MMF) is an effective immunosuppressant that
does not lead to mucositis, we hypothesized that a combination of these 2 oral agents may be an effective GVHD
prophylactic strategy.We, therefore, designed anoutpatient prospective cohort studywith a conditioning regimen
consisting of fludarabine (Flu) 30 mg/m2 daily and cyclophosphamide (Cy) 300 mg/m2 daily for 5 days followed
by infusion of blood stem cells. Tacrolimus 3 mg twice a day was started on day (D)28, adjusted to achieve levels
10-15 nmol/L, continued untilD150 and then tapered byD1100or1180 according to estimated riskof relapse.
MMF 1000 mg twice a daywas started onD11 and discontinuedonD150. To date, 131 patients (males/females:
75/56) with a median age of 54 years have received a 6/6 matched sibling transplant using this protocol. Indication
for NMA transplant included age .55 years (24%), expected increased risk of toxicity (28%), or participation
in a multiple myeloma (MM) sequential protocol (48%). Most common diagnoses included MM (N5 62), non-
Hodgkin lymphoma (NHL, N5 46), and acute leukemia (N5 10). Following infusion of 6.8 106 CD341
cells/kg (range: 0.30-22.3), neutrophil and lymphocyte engraftment occurred in 95% of patients by D 1180.
The estimated cumulative incidence of classical grade I-IVaGVHDbyD1120was 11.6% (95% confidence interval
[CI]: 7.1-18.5). No grade IV aGVHD was observed. In addition, 15 patients (12%: CI: 7.4-19.2; median D1140)
developed an overlap syndrome consisting of clinical and histologic features of both aGVHD and cGVHD simul-
taneously. The estimated cumulative incidence of extensive cGVHDwas 76.1% (95%CI: 67.4-83.9) at 2 years,with
clinical features at presentation similar to other reported series. In patients developing extensive cGVHD, the
probability of remaining on immunosuppression at 5 years was 34.8% (95% CI: 16.4-57.3). With a median fol-
low-up of 982 days, the estimated probabilities of nonrelapse mortality (NRM) and overall survival (OS) were
15.5% (95% CI: 9.0-26.1) and 62.7% (95% CI: 51.4-72.1). The cumulative incidence of relapse was 30% at 7 years.
FollowingNMAtransplant, disease-free survival (DFS)washighest in recipientswith follicularNHL (79.8%: 95%CI:
57.6-91.2) and lowest in large cell NHLs (34.3%: 95% CI: 1.6-75.9). From this large group of patients treated with
a uniform conditioning and GVHD prophylaxis regimen, we conclude that aGVHD prophylaxis with early use of
tacrolimus and MMF is safe, effective, and associated with low NRM. Future strategies will need to focus on
decreasing the incidence of extensive cGVHD without increasing the risk of relapse.
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920 Biol Blood Marrow Transplant 15:919-929, 2009W. Sabry et al.INTRODUCTION Patients with chronic myelogenous leukemia (CML)Nonmyeloablative (NMA) allogeneic hematopoi-
etic stem cell transplantation (HSCT) was designed
to decrease transplant-related complications and
mortality, thus broadening access to transplantation
to older and sicker patients [1-5]. Surprisingly, despite
a presumably attenuated cytokine storm, the incidence
of classical acute graft-versus-host disease (aGVHD)
remains high, with reported cumulative incidence
of grades II-IV up to 60% [1-5]; serious aGVHD
or chronic GVHD (cGVHD) (following NMA
transplant) has detrimental consequences in patients
including death, disability, infections, or prolonged
hospitalization [6,7]. These variations in incidence
and severity between series most likely reflect hetero-
geneity of both transplant populations and of aGVHD
prophylaxis regimens.
Despite the large numbers of NMA transplants
performed worldwide, there is no consensus yet on
the best conditioning and GVHD prophylaxis regi-
mens. An ideal NMA conditioning regimen should
be sufficiently immunosuppressive to ensure high
engraftment rates and associated with minimal post-
transplant toxicity. Posttransplant immunosuppres-
sion should be maintained at a level low enough to
allow a graft-versus-tumor (GVT) effect, but also
sufficient to lead to acceptable rates of aGVHD and
cGVHD. We report herein the results of a large, ho-
mogenous cohort of 131 patients treated with a novel
NMA transplant conditioning and GVHD prophy-
laxis regimen characterized by outpatient use of fludar-
abine (Flu) and cyclophosphamide (Cy) with early
introduction of tacrolimus to achieve therapeutic
levels at time of graft infusion.MATERIALS AND METHODS
Conditioning Regimen, aGVHD Prophylaxis,
and Treatment
The NMA conditioning regimen and immunosup-
pression withdrawal schedule were designed to permit
the GVT effect associated with cGVHD [3] with
a view to reduce the incidence of aGVHD. It was
also intended to perform the NMA transplant as an
outpatient procedure. The conditioning regimen con-
sisted of Cy 300 mg/m2 intravenously (i.v.) daily and
Flu 30 mg/m2 i.v. daily for 5 days from day (D) 28
to D24, given from Monday to Friday in our ambula-
tory facility. Tacrolimus was selected because of its ef-
ficacy in preventing aGVHD and its potential role in
preventing graft rejection [8-10]. Tacrolimus was
started at 3 mg twice a day orally on D 28, and ad-
justed thrice weekly until D150 to achieve trough se-
rum levels of 10-15 nmol/L, then tapered by D 1100
(high-risk patients) or D1180 (standard-risk patients).in chronic phase, acute myelogenous leukemia
(AML) in first complete remission (CR1), acute lym-
phoblastic leukemia (ALL) in CR1, or refractory ane-
mia (with or without ring sideroblasts [RA, RARS])
were considered standard risk; high-risk disease in-
cluded all others. Donors received granulocyte-colony
stimulating factor (G-CSF) 5 mg/kg twice a day for 9
doses and were collected by consecutive daily apheresis
until at least $5 106 CD341 cells/kg recipient
weight had been collected. Allogeneic stem cells
were reinfused on day 0 after storage at 4C overnight;
no attempt was made to limit the number of CD341
cells infused [11]. Mycophenolate mofetil (MMF)
was used instead of methotrexate (MTX) to avoid mu-
cositis. It was initiated at 1000 mg twice a day 24 hours
after the last infusion of stem cells and discontinued
without tapering on D 150. MMF was not adjusted
for recipients’ weight and levels were not performed.
aGVHD and cGVHD were graded according to pre-
viously reported criteria after exclusion of infectious
or other causes; all efforts were made to obtain a tissue
biopsy to confirm diagnosis [12,13]. Distinguishing
aGVHD from cGVHD was not restricted to time to
symptomatic onset and clinical presentation was con-
sidered according to recent consensus criteria [14].
Grade I classical aGVHD was treated with topical ste-
roids only; treatment of grade II-IV classical aGVHD,
overlap syndrome, and cGVHD has been described in
detail before [15].
Following infusion, all recipients were assessed in
the outpatient clinic thrice weekly with appropriate
clinical, hematologic, and biochemical evaluations un-
til neutropenia resolved; regular follow-up visits were
then undertaken as clinically indicated. Irradiated red
blood cells (RBCs) and platelets were transfused if
the hemoglobin #85 g/L or the platelet count was
#15 109/L.Eligibilty Criteria
This prospective cohort study was conducted at
Maisonneuve-Rosemont Hospital, Montreal, Que-
bec, Canada, a 725-bed tertiary care hospital ac-
credited by the Foundation for Accreditation of
Cellular Therapy. All patients were treated and fol-
lowed at 1 site by the same HSCT team; they were
eligible to participate in this protocol if they were
65 years old or less, had a recognized indication for
allogeneic transplant according to predetermined in-
stitutional criteria for NMA allogeneic transplanta-
tion, and a 6/6 HLA compatible sibling donor.
Mismatched sibling or unrelated transplant candi-
dates were excluded. Eligible patients were offered
treatment on this protocol either because they were
too unfit to undergo standard myeloablative (MA)
transplant or because they were between the ages of
Biol Blood Marrow Transplant 15:919-929, 2009 921GVHD Prophylaxis with Tacrolimus and MMF55 and 65 years. Finally, patients with newly diag-
nosed multiple myeloma (MM) were invited to par-
ticipate in a sequential therapy protocol consisting
of autologous transplantation followed by NMA
transplant. Written informed consent was obtained
from all patients after approval by our institutional
review board.
Infectious Prophylaxis
Trimethoprim/sulfametoxazole, 1 double-strength
tablet twice a day on Saturdays and Sundays, was
given for Pneumocystis jirovecii prophylaxis starting
D 23 and continued until discontinuation of all im-
munosupppression. Patients who were seropositive
for herpes simplex received acyclovir 200 mg three
times a day from D 28 until D 121. Cytomegalo-
virus (CMV) seropositive recipients or recipients
transplanted from a CMV-seropositive donor were
followed using a preemptive approach of weekly
antigenemia or quantitative polymerase chain reac-
tion (PCR) testing from D 114 until D 198, after
which routine surveillance was discontinued. Patients
with a positive CMV antigen or PCR were promptly
treated with i.v. ganciclovir accordingly to a standard
algorithm [16]. No other antimicrobial or antifungal
prophylaxis was used. Immunoglobulins and G-CSF
were not routinely administered after transplant.
Engraftment
Chimerism studies were performed using short
variable tandem repeats by PCR assay (GenePrint
STR Systems, Promega, Madison, WI) in both lym-
phocytes and neutrophils every 2 weeks for the first 8
weeks, then monthly for 2 months, and every 3 months
for 5 years then yearly thereafter. We defined engraft-
ment (complete donor chimerism [CDC]) when lym-
phocytes and neutrophils were both $95% donor
origin. For patients not achieving CDC after D
1120 despite withdrawal of imunosuppression and
those with persistent or progressive disease, the initial
intention was to administer 3 monthly donor lympho-
cyte infusions (DLIs) of 1 107 CD31 cells/kg each.
Because of high incidences of engraftment and
cGVHD, DLIs were subsequently given only for per-
sistent or progressive disease.
Statistical Analysis
The primary objective of this prospective cohort
study was to determine the incidence and severity of
classical aGVHD and cGVHD in patients who re-
ceived this conditioning regimen and GVHD prophy-
laxis. Secondary objectives included measurement of
engraftment rates, pattern of engraftment in both
lymphocytes and neutrophils, duration of cytopenias,
transfusion requirements, feasibility to conduct the
procedure as an outpatient, and description of out-come according to disease (lymphoma versus MM
versus leukemia). Data were analyzed with Stata 8.0
(StataCorp, College Station TX). Proportions were
compared with the c2 test or, when numbers were
small, with Fisher’s exact test. Unconditional logistic
regression was used for multivariate analysis. Results
are expressed as crude (CHR) and adjusted hazard ra-
tios (AHR) with their 95% confidence intervals (CI).
Models were built sequentially, starting with the vari-
able most strongly associated with the outcome and
continuing until no other variable reached significance
or altered the hazard ratios of variables already in the
model. Descriptive statistics, Kaplan-Meier (KM) in-
cidence estimates for classical aGVHD and cGVHD,
CDC, overall survival (OS), and disease-free survival
(DFS) were calculated with the statistical package
Prism 4.0 (GraphPad Software, San Diego, CA). OS
was defined as time from transplant to death from
any cause. DFS was defined as time from transplant
to the first event of either relapse or death.RESULTS
Demographics
Between July 2000 and December 2007, 131 pa-
tients were enrolled and followed prospectively after
HSCT. Median follow-up is 982 days (range: 80-
2576). Patient characteristics are presented in Table 1.
Median age was 54 years (range: 20-66 years), and most
patients (57%) were male. The most common disease-
related indications for transplant were MM (N5 62,
47%) and non-Hodgkin lymphoma (NHL, N5 46,
35%), with most patients having indolent histology
(N5 28, 61%). Among MM patients, 54 received
planned sequential treatment, whereas 8 were allo-
transplanted after relapsing from autologous trans-
plant. Other indications for NMA transplant were
age $55 years (24%) and expected high toxicity with
conventional regimen as judged by attending trans-
plant physician (28%). Most patients (60%) had re-
ceived less than 2 chemotherapy regimens and 87%
were in CR or partial remission (PR) prior to NMA.
Overall, 101 (77%) had previously received autologous
HSCT (average of 10 months; range: 2-135). Less than
half (42%) of recipients were at risk for CMV disease;
26% were males who received a graft from a female do-
nor. G-CSF was used in only 22 patients (16%) for
a median of 3 days (range: 1-7) for neutropenic fever
(N5 3), drug induced neutropenia (N5 2), pneumo-
nia (N5 1), or prevention of neutropenic fever in frail
patients (N5 16).
Grafts and Engraftment
The median numbers of infused mononuclear and
CD341 cells were 9.6 108/kg (range: 1.2-23.6) and
6.8 106/kg (range: 0.30-22.3), respectively. One
Table 1. Shown Are Demographics of 131 Patients Who
Received Outpatient Nonmyeloablative (NMA) Transplant
N5 131 (%)
Age (years)
Median: 54 (range: 20-66)
Sex
Male 75 (57)
Diagnosis
Multiple myeloma 62 (47)
Sequential protocol 54 (41)
Relapsed 8 (6)
Non-Hodgkin lymphoma 46 (35)
Low grade 28 (21)
Large cell 10 (8)
Mantle 7 (5.3)
Sezary 1 (0.7)
Acute myelogenous leukemia 8 (6)
Acute lymphoblastic leukemia 2 (1.5)
Myelodysplastic syndrome 4 (3)
Chronic myelogenous leukemia 2 (1.5)
Chronic lymphocytic leukemia 4 (3)
Hodgkin disease 3 (2.3)
Indication of NMA transplant
Age 31 (24)
Expected toxicity 37 (28)
Sequential protocol Prior regimens 63 (48)
0-2 78 (60)
3-5 41 (31)
6-9 12 (9)
Clinical status at NMA transplant
Complete remission 49 (37)
Partial remission 66 (50)
Stable 9 (7)
Progressive disease 7 (5)
Donor/recipient CMV status
2/2 48 (37)
2/+ 28 (21)
+/2 28 (21)
+/+ 27 (21)
Donor/recipient sex pairs
Male/Male 41 (31)
Male/ Female 30 (23)
Female/Male 34 (26)
Female/ Female 26 (20)
CMV indicates cytomegalovirus.
Patients with a diagnosis of follicular, small lymphocytic, and lymphoplas-
macytic lymphoma are included in the low-grade category.
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Figure 1. Shown are patients who achieved $95% donor cells in
granulocytes and lymphocytes following NMA transplant. Patients
with either relapse (R), missing specimens (ND), or who died (D)
were excluded from denominators.
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106/kg CD341 cells) required emergency bone mar-
row harvest and 1 heavily transfused patient (.30
transfusions) with myelodysplastic syndrome (MDS)
received equine antithymocyte globulin (ATG)
10 mg/kg for 3 days in addition to Flu and Cy. In total,
11 patients were unavailable for engraftment analysis,
either because of early progression/death (before D
190) with transfer to palliative care or lost to follow-
up (N5 1); median time of death for these 11 patients
was D1138 (range: 80-190). In the remaining 120 pa-
tients evaluable for engraftment, almost 95%
(N5 114) achieved CDC by D 1180 (Figure 1). We
observed no statistically significant difference in time
to engraftment between lymphocytes and neutrophils.
There were 16 patients who received DLIs, including
5 for mixed chimerism (days 1107, 1108, 1111,
1156, and 1265) and 11 for progressive disease. Todate, we report no case of late graft failure. Neutrope-
nia defined as #0.2 109/L or# 0.5 109/L was
observed in 57% (median duration 3 days; range:
0-18 days) and 80% (median duration 10 days; range:
2-27 days) of the 131 patients, respectively. Platelet
counts #20 109/L was seen in only 6% (median
duration 1 day; range: 0-10 days). Packed RBC transfu-
sions were administered to 40 (31%) patients (median
of 3 units; range: 1-26), and platelet transfusions to
17 (13%) patients (median 10 units; range: 5-30).GVHD
At a median of 69 days (range: 31-129 days), 15 pa-
tients developed grade I-IV classical aGVHD (cumu-
lative incidence 11.6%; 95% CI: 7.1-18.5), including
5 grade I, 7 grade II, 3 grade III, but no grade IV (Ta-
ble 2). Skin and gastrointestinal (GI) involvement was
present in 13 (87%) and 4 patients (27%) respectively;
no patient experienced hepatic aGVHD. In addition,
15 patients (Table 3) developed an overlap syndrome
(cumulative incidence 12%; 95% CI: 7.4-19.2) with
clinical and histologic features of both acute (diarrhea
$500 mL/24 hours) and cGVHD at a median of 140
days (range: 92-177). Interestingly, all patients who
underwent colonic biopsy had histologic changes con-
sistent with aGVHD. Liver involvement manifested by
either hyperbilirubinemia (N5 3) or increased liver
enzymes (N5 6). Altogether, the cumulative inci-
dence of classical aGVHD (grade II-IV) and overlap
GVHD was 19.7% (95% CI: 13.7-27.7; Figure 2). In-
fusion of $10 106 CD341/kg and achieving full
CDC by D128 were significant risk factors for devel-
opment of grade II-IV acute/overlap syndrome in uni-
variate analysis (Table 4). Following multivariate
analysis, only achievement of full engraftment by D
Table 2. Shown Are Day of Onset and Organ Stage in 15
PatientsWho Presented with Classic Acute Graft-versus-Host
Disease
Patient Day of Onset
Organ Stage
Overall
GradeSkin Gastrointestinal Liver
1 31 2 0 0 I
2 35 2 0 0 I
3 36 3 0 0 II
4 49 0 3 0 III
5 50 1 0 0 I
6 53 2 0 0 I
7 59 3 0 0 II
8 69 3 0 0 II
9 70 2 0 0 I
10 76 2 3 0 III
11 80 3 0 0 II
12 90 3 0 0 II
13 96 3 0 0 II
14 113 1 1 0 II
15 128 0 3 0 III
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Figure 2. Compares incidences of classic grade II-IV aGVHD (7.7 %)
and overlap syndrome (12 %).
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engraftment by D128 were 3 times more at risk of suf-
fering from classical aGVHD or overlap syndrome
(P5 .018).
In contrast, cumulative incidence of extensive
cGVHD was 76.1% at 2 years (N5 87, 95% CI:
67.4-83.9%). Day of presentation ranged from 83 to
1146 (median 153 days). Most frequently involved or-
gans included mouth (100%), skin (89%), and liver
(65%). The following variables were examined for po-
tential risk factors of extensive cGVHD: age at trans-
plant, sex, indication for transplant, infused CD341
cells, donor/recipient CMV status, chimerism status
at D 128. Intriguingly, the only significant risk factor
for development of extensive cGVHD was infusion of
\10.0 106 CD341/kg cells (CHR 1.9, 95% CI: 1.1-
3.3, P5 .03). The probability of taking any immuno-
suppressive medication after NMA transplant de-Table 3. Clinical Presentation in 15 Patients with an Overlap
Syndrome Consisting of Diarrhea$ 500 mL/Day and Clinical/
Histological Features of Chronic GVHD Involving Eyes (Sicca
Syndrome), Mouth (Lichen Planus), Skin (Erythematous
Maculopapular Rash), Liver (Cholestasis, Increased Liver En-
zymes), Joints (Synovitis), and Lungs (BronchiolitisObliterans)
Patient Day of Onset Eyes Mouth Skin Liver Joints Lungs
1 92 X X X
2 113 X
3 121 X X X X
4 127 X
5 130 X X X
6 138 X X X X
7 139 X X X
8 140 X X X
9 140 X X
10 140 X X
11 148 X X X X
12 150 X
13 153 X X X
14 163 X X X
15 177 X X Xcreased steadily over time and is estimated at 34.8%
(95% CI: 16.4-57.3) 5 years after HSCT (Table 5).
Transplant-Related Complications
and Outcome
Over the study period, 37 patients died: 24 from
relapse and 13 from other causes. With a median fol-
low-up of 982 days (range: 80-2576 days), we observed
a nonrelapse mortality (NRM) of 15.5% (95% CI: 9.0-
26.1) at 7 years (Figure 3). Other causes of death in-
cluded complications directly related to cGVHD
(n5 3), fulminant hepatitis, disseminated aspergillo-
sis, adult respiratory distress syndrome (ARDS) of un-
clear etiology, encephalopathy of unknown cause,
ruptured aortic aneurysm, anterior myocardial infarc-
tion, legionellosis, and massive intraabdominal hemor-
rhage secondary to anticoagulation. No patient died of
aGVHD.
OS for the entire cohort at 1, 3, and 7 years was
88.6% (95% CI: 81.7-92.9), 73.4% (95% CI: 63.9-
80.8), and 62.7% (95% CI: 51.5-72.1), respectively
(Figure 4), with a median follow-up for survivors of
40.5 months (range: 11-86). Patients with follicular
NHL had the best OS at 3 years (78.7%; 95% CI:
55.2-90.8), similar to patients with large cell NHL
(67.5%; 95% CI: 16.2-91.9) and MM (73.1%; 95%
CI: 58.4-83.3) (Figure 5). In contrast, DFS at 3 years
was clearly best for follicular NHL at 78.7% (95%
CI: 55.2-90.8), significantly higher than for patients
with MM (47.6%, 95% CI: 33.3-60.5, CHR 2.7,
P5 .04) and leukemia/MDS (42.9%, 95% CI: 17.8-
66.0, CHR 4.7, P5 .007); DFS at 3 years was also
best for patients with follicular NHL when compared
to large cell NHL (34.3%, 95% CI: 1.6-75.9) or other
types of NHL (75%, 95% CI: 12.8-96.1, Figure 6).
Overall, incidence of CMV viremia was 31.2%; 29
of 55 (53%) CMV seropositive recipients developed
Table 4. Recipients’ Risk Factors for Classic Grade II-IV Acute GVHD and Overlap Syndrome (6 Months Follow-up)
Patients with
GVHD/Total
Incidence (%)
of GVHD
Crude Hazard
Ratio (95% CI)
Adjusted Hazard
Ratio (95% CI)*
Cohort overall 25/131 19.7
Age at time of transplant (years)
20-49 9/39 24.5 1.00 1.00
50-59 11/57 19.6 0.85 (0.35-2.04) 0.80 (0.33-1.94)
$60 5/35 14.8 0.64 (0.22-1.92) 0.68 (0.23-2.03)
Sex
Female 11/56 20.1 1.00 1.00
Male 14/75 19.4 0.95 (0.43 - 2.08) 1.15 (0.51-2.58)
Indication for transplant
MM 15/62 24.7 1.00 1.00
NHL, low grade 6/28 21.4 0.87 (0.34 – 2.25) 0.77 (0.30-1.98)
NHL, large cell 1/10 10.0 0.37 (0.05-2.79) 0.21 (0.03-1.64)
NHL, other 1/8 12.5 0.50 (0.07-3.78) 0.44 (0.06-3.39)
Leukemia/MDS 1/14 7.1 0.33 (0.04-2.52) 0.14 (0.02-1.15)
Other 1/9 11.1 0.43 (0.06-3.24) 0.43 (0.06-3.24)
Infused CD34+ cells (106/kg)
<10.0 16/103 15.1 1.00 1.00
$10.0 9/28 33.4 2.34 (1.03-5.30)† 2.04 (0.89-4.69)†
Donor/recipient CMV status
Negative/negative 9/48 19.0 1.00 1.00
Other 16/83 20.0 1.06 (0.47-2.39) 1.15 (0.51-2.61)
Donor/recipient sex combinations
Female/male 4/34 11.8 0.49 (0.17-1.41) 0.55 (0.19-1.60)
Other 21/97 22.4 1.00 1.00
Chimerism status D +28
Partial 15/99 15.6 1.00 1.00
Full engraftment 10/28 37.1 2.99 (1.34- 6.66)‡ 2.99 (1.34-6.66) ‡
MM indicates multiple myeloma; NHL, non-Hodgkin’s lymphoma; MDS, myelodysplastic syndrome; CMV, cytomegalovirus; GVHD, graft-versus-host
disease; CI, confidence interval; D, died.
*Adjusted for chimerism status at D +28.
†P5.09.
‡P5.007.
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negative patients who received grafts from seropositive
donors. Only 3 patients (2 with pneumonia, D 1682
and 11053; 1 with CMV colitis, D 1930) developed
CMV disease with favorable outcome. Herpes zoster
infection was commonly observed with an incidence
of 35%. Invasive aspergillosis was diagnosed in 13
patients and was directly the cause of death in 2.
The NMA allogeneic transplant regimen described
herein was initially designed to be performed on an out-
patient basis. Within the first 100 days, 29 patients
(22%) were admitted to the hospital, at a median of
D 132 (range: 0-95). Reasons for admission included
neutropenic fever (n5 7), active infection (n5 12),
disease progression (n5 1), aGVHD (n5 2), hemorra-
gic cystitis (n5 2), interstitial pneumonitis (n5 1),
neutropenic colitis (n5 1), and infectious enteritis
(n5 3). Between D1101 and D1180, 21 additional pa-Table 5. Shown Is the Prevalence of Patients Taking Any Immunos
Folow-up Completed 1 Year 2 Yea
Patients followed 112 84
Patients taking immunosuppression Yes 91 61
No 21 23
% Taking immunosuppression 81.3 72.6
Confidence interval 72.8-88.0 61.8-81tients (17% of 129 evaluable patients) were hospitalized
(median time D1149; range 123-178) for the following
reasons: complications related to GVHD (N5 10), ac-
tive infection (n5 6), disease progression (n5 2), fulmi-
nant hepatitis (n5 1), thrombocytopenic purpura
(n5 1), and gastric perforation with septic shock
(n5 1). In total, 38 (29%) patients were never hospital-
ized during the observation period.DISCUSSION
An effective GVT effect following NMA alloge-
neic HSCT is well described [1,2,17-22]. NMA regi-
mens are particularly appealing for older or frail
patients who are at higher risk of transplant-related
complications with myeloablative transplantation;
additionally, the ability to perform transplant on anuppression According to Time Posttransplant
rs 3 Years 4 Years 5 Years 6 Years
61 38 23 12
41 26 8 3
20 12 15 9
67.2 68.4 34.8 25.0
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Figure 3. Shows an incidence of non relapse mortality of 15.5% (95%
CI: 9.0-26.1) at 7 years in a cohort of 131 patients who received
NMA transplant.
Biol Blood Marrow Transplant 15:919-929, 2009 925GVHD Prophylaxis with Tacrolimus and MMFoutpatient basis remains attractive from both a patient
and healthcare utilization perspective [23,24].
aGVHD following NMA transplant is still a challeng-
ing problem with a reported incidence between 20% to
60% [2,19,25-27]. GVHD prophylaxis regimens
remain currently heterogenous with no consensus
regarding the best regimen to use.
Tacrolimus, a calcineurin inhibitor, has interesting
properties as an agent for prevention of aGVHD,
notably in vitro immunosuppressive effects approxi-
mately 100 times higher than cyclosporine A (CsA)
[28]; the combination of tacrolimus with MTX has
led to a significant reduction in incidence of aGVHD
compared to CsA/MTX, with similar toxicity and re-
lapse rates [6,7]. In contrast to MTX, which is well
known to cause mucositis [29], MMF has minor muco-
sal and hematologic toxicities. This advantage has led
to replacement of MTX by MMF in a few NMA series
[30-34]. Synergy between tacrolimus and MMF in
preclinical models [35,36], as well as the negative0
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Figure 4. Shows an OS of 62.7% (95% CI : 51.5-72.1) at 7 years for the
whole cohort of 131 patients.effects of CsA on MMF trough levels [37,38] moti-
vated us and others [39-41] to study this combination.
This prospective study of 131 patients is the largest
published cohort of NMA transplant recipients from
a single center who received uniform GVHD prophy-
laxis using a combination of tacrolimus and MMF.
The incidence of classical grade I-IV aGVHD
(11.6%) is markedly lower than the incidences of
18.5% and 85% reported by other investigators
[40,41], as is the observed incidence of grade II-IV
(3.8% versus 15.6% and 42%) and III-IV (1.5% versus
3% and 29%) aGVHD [40,41]. Of note, no grade IV
classical aGVHD was observed in this study; intrigu-
ingly, skin and gut were the only organs affected with
no patient presenting hepatic involvement. Our cumu-
lative incidence of classical aGVHD is also lower than
in a series that used CSA/MMF and/or MTX (range:
44%-71%) in the setting of NMA transplant
[6,19,22,42-47]. Classical aGVHD occurred at a me-
dian of 69 days (range: 31-120 days), similar to other
series using tacrolimus/MMF [40], but later than a se-
ries using CsA/MMF [45]. Following multivariate
analysis, achievement of full chimerism by D 128
was the only significant risk factor for development
of grade II-IV aGVHD, a finding observed previously
in animal and human studies [18,48,49].
The reasons for such a low incidence of aGVHD
and peculiar clinical presentation remain uncertain.
The early start of tacrolimus (D28) in our study com-
pared to D 23 [40] or D 12 [41] might have contrib-
uted to the observed lower incidence by earlier
achievement of therapeutic levels. Second, inclusion
of matched unrelated transplants in Jillella et al’s study
[41] (25% of patients) might have increased the inci-
dence and severity of GVHD. Third, we speculate
that the use of Cy and Flu as NMA conditioning might
have attenuated the cytokine ‘‘storm,’’ which occurs in
the peritransplant period, thereby also contributing to
the lower incidence of classical aGVHD.
In addition to a low incidence of classical aGVHD,
we observed, similar to the Seattle group, a syndrome
of late-onset aGVHD in a minority (12%) of our pa-
tients [44]. We elected not to use the term ‘‘late-onset
aGVHD,’’ because unlike patients described by Miel-
carek et al. [44], our 15 patients also had features of
cGVHD, a reason we elected to classify them as having
an ‘‘overlap syndrome.’’ Patients with an overlap syn-
drome underwent colonic biopsies, which revealed
histologic changes consistent with aGVHD [50]. Fea-
tures of cGVHD across a wide time range (33-832 days
after transplant) with histologic findings consistent
with aGVHD in biopsied specimens have also been
documented in other studies [51,52]. Current consen-
sus is that clinical manifestations, and not time to
symptomatic onset after transplantation, determine
whether the clinical syndrome of GVHD is considered
acute or chronic [14].
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Figure 5. Shown is the estimated OS in our 131 patients according to initial diagnosis. NHL, non Hodgkin lymphoma; MM, multiple myeloma; DLCL,
diffuse large-cell lymphoma.
926 Biol Blood Marrow Transplant 15:919-929, 2009W. Sabry et al.In contrast with our reported very low incidence of
classical aGVHD, we observed an incidence of exten-
sive cGVHD of 76% at 2 years, whereas limited
cGVHD was present in only a minority (4.6%). Com-
pared to other series using tacrolimus and MMF, our
incidence of extensive cGVHD is lower than the
87% reported by Jillella et al. [41], but higher than
the 42% reported incidence by Nieto et al. [40].
Similar to our cohort, limited cGVHD was uncom-
mon in both studies (7.7% and 4.3%, respectively).
In a mixed cohort using tacrolimus/MMF or CSA/
MMF, Rezvani et al. [22] reported a 47% incidence
of extensive cGVHD, whereas other studies using
CSA/MMF6MTX reported ranges between 41%
and 73% [6,22,42,46,47] with higher incidence if
MTX was added [45]. Despite such a relatively high in-
cidence of cGVHD in our cohort, organ involvement
at initial presentation was similar to other studies
[53,54]. With a median follow-up of 33 months, prob-0
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Figure 6. Shown is the estimated DFS in 131 patients according to initial diag
fuse large-cell lymphoma.ability to take immunosuppression in our cohort is also
comparable to other reported studies [55].
Many studies have reported at least a trend toward
higher incidences of cGVHD following NMA when
compared to MA transplant [20,46,56]. One study re-
ported similar [44], whereas another, a lower incidence
(14% versus 40%) [57]. An incidence of cGVHD of
76% in our cohort, despite a very low incidence of
classical aGVHD, a well-known risk factor of cGVHD,
is poorly understood, although some authors have
suggested that increased patients’ age [46] or using
G-CSF mobilized peripheral blood stem cells (PBSCs)
might play a role [55]. Our observation of a lower inci-
dence of cGVHD in recipients who have received more
CD341 cells remains unexplained. The change in pat-
tern of GVHD following NMA HSCT might be be-
cause of factors such as decreased inflammatory
cytokine release [44,58,59], better tolerance resulting
from mixed donor-host chimerism [57,60], as well asFollicular NHL (N=26)
MM (N=62)
Other Diseases (N=23)
6 7
DLCL (N=10)
Other NHL (N=10)
nosis. NHL, non Hodgkin lymphoma; MM, multiple myeloma; DLCL, dif-
Biol Blood Marrow Transplant 15:919-929, 2009 927GVHD Prophylaxis with Tacrolimus and MMFhigher numbers of host antigen presenting cells that
play a role in initiation of GVHD [58,61].
Our cumulative incidences of NRM and OS
(10.2% and 73.4% at 3 years, 15.5% and 62.7% at 7
years) are comparable to that reported by Jillela et al.
[41] (7% and 71% at 2.8 years), and Nieto et al. [40]
(15.6% at 2 years and 62.5% at 19 months), respec-
tively, with a longer follow-up in favor of our cohort.
In contrast, several other studies have reported less fa-
vorable outcomes, including Falda et al. (10% and
53% at 1 year), Rezvani et al. (42% and 43% at 3
years), Alyea et al. (32% at 3 years and 51% at 2 years)
and Koh et al. (27% at 1 year and 46% at 22 months)
[22,26,42,45,62]. Relapse rate at 7 years is 30%, lower
than most reported series, ranging from 46% to 53%
[26,42,44]. DFS rates for indolent and aggressive
NHL are better than what has been reported in other
studies [22], but comparable [63] or better than other
series of MM [64,65]. The relatively high incidence
of cGVHD in our cohort, potentially associated with
better GVT effect, might have contributed to lower
the mortality rate and improve OS in our patients
[66]. Finally, inclusion of less than one-third of pa-
tients with aggressive disease subtypes might have con-
tributed to the favorable outcome observed in our
cohort.
In conclusion, NMA transplant using a condition-
ing regimen of Flu/Cy with early introduction of ta-
crolimus (D 28) followed by addition of MMF for
GVHD prophylaxis until D 150 is associated with
high engraftment rates (95%), a very low incidence
of classical aGVHD, and an overlap syndrome alto-
gether with excellent NRM, OS, and DFS. Our obser-
vation of an overlap syndrome with clinical features of
both aGVHD and cGVHD strengthens the notion
that the traditional D 1100 separation of aGVHD
and cGVHD should be abandoned and other charac-
teristics such as GVHD-related symptoms and severity
be considered in the setting of NMA transplant
[6,44,46]. Future strategies to decrease the incidence
of cGVHD while preserving antitumor activity are
warranted.
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